QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. We specialize in providing solutions for molecular diagnostics, applied testing, academic and pharmaceutical research and other fields. The company operates in over 25 countries worldwide and has a broad customer base that includes researchers, clinicians and other professionals.

One of QIAGEN's flagship products is the QIAstat-Dx syndromic testing platform, a multiplexed molecular diagnostic system that enables rapid detection of a variety of pathogens linked to infectious diseases. QIAstat-Dx is designed to provide accurate and reliable results in about an hour, allowing for faster diagnosis and treatment of patients. The system uses proprietary technology that allows for simultaneous detection of multiple pathogens in a single sample, reducing the need for separate tests and saving time and resources.

QIAstat-Dx is highly user-friendly, with an intuitive touchscreen interface and minimal hands-on time. The system can support the work of clinicians in a variety of settings, including hospitals and clinics, and is ideal for situations where rapid diagnosis is essential. It is also highly flexible, with the ability to run a variety of different assays depending on the needs of the user. In May 2022, we announced the QIAstat-Dx Rise (coming soon) – a high-capacity version of the QIAstat-Dx.

Both platforms run on pre-packaged cartridges (panels) that contain all the necessary reagents and components to perform a particular assay. These panels are designed to provide fast, accurate and reliable detection of a variety of pathogens linked to infectious diseases, including respiratory infections, gastroenteritis and meningitis/encephalitis. This allows for faster diagnosis and treatment of patients, helping to improve patient outcomes and reduce the spread of infectious diseases.

To learn more about QIAstat-Dx, visit https://www.qiagen.com/qiastat-dx.